New drug combo aims to wipe out tough leukemia in adults
NCT ID NCT06253637
First seen Mar 11, 2026 · Last updated May 14, 2026 · Updated 10 times
Summary
This study tests whether adding daratumumab to standard chemotherapy can eliminate all signs of leukemia in adults with a very high-risk form of T-cell acute lymphoblastic leukemia. About 31 participants aged 18 to 65 will receive the drug combination during their first treatment cycle. The goal is to see if more patients achieve a deep remission with no detectable cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-LYMPHOCYTIC LEUKEMIA, ACUTE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ematologia AOU Careggi
Florence, Italy
-
Ematologia AOU Policlinico Umberto I
Roma, Italy
-
Ematologia P.O. Vito Fazzi - Lecce
Lecce, Italy
Conditions
Explore the condition pages connected to this study.